FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

24 results

abrilada
(adalimumab-afzb)
Pfizer Laboratories Div Pfizer Inc
Usage: ABRILADA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients.
actemra
(tocilizumab)
Genentech, Inc.
Usage: ACTEMRA (tocilizumab) is indicated for treating moderately to severely active rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis, severe cytokine release syndrome, and COVID-19 in hospitalized adults receiving systemic corticosteroids.
adalimumab-ryvk
(adalimumab-ryvk)
Quallent Pharmaceuticals Health LLC
Usage: Adalimumab-ryvk is indicated for various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis, aiming to reduce symptoms and inhibit disease progression.
amjevita
(adalimumab-atto)
Amgen Inc
Usage: AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.
avtozma
(tocilizumab)
CELLTRION USA, Inc.
Usage: AVTOZMA® (tocilizumab-anoh) is indicated for adults with moderately to severely active rheumatoid arthritis, giant cell arteritis, and hospitalized adults with COVID-19. It also treats active polyarticular and systemic juvenile idiopathic arthritis in patients aged 2 years and older.
cyltezo
(adalimumab-adbm)
Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.
enbrel
(etanercept)
Immunex Corporation
Usage: Enbrel is indicated for reducing signs and symptoms in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, chronic moderate to severe plaque psoriasis, and active juvenile psoriatic arthritis in patients aged 2 and older, with or without methotrexate.
jylamvo
(Methotrexate)
SHORLA ONCOLOGY INC.
Usage: JYLAMVO is indicated for treating acute lymphoblastic leukemia in adults and pediatric patients, mycosis fungoides, relapsed non-Hodgkin lymphomas, rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in pediatrics, and severe psoriasis in adults.
kevzara
(sarilumab)
sanofi-aventis U.S. LLC
Usage: KEVZARA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis and polymyalgia rheumatica who have had inadequate responses to DMARDs or corticosteroids. It is also indicated for active polyarticular juvenile idiopathic arthritis in patients weighing 63 kg or more.
methotrexate
(Methotrexate)
Chartwell RX, LLC
Usage: Methotrexate tablets are indicated for treating neoplastic diseases (acute lymphoblastic leukemia, mycosis fungoides, relapsed non-Hodgkin lymphomas), rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in pediatric patients, and severe psoriasis in adults.

Medications for Polyarticular Juvenile Idiopathic Arthritis Rheumatoid Factor Negative

abrilada

actemra

adalimumab-ryvk

amjevita

avtozma

cyltezo

enbrel

jylamvo

kevzara

methotrexate